...
首页> 外文期刊>The Egyptian Rheumatologist >HLA-DRB1 alleles in Egyptian rheumatoid arthritis patients: Relations to anti-cyclic citrullinated peptide antibodies, disease activity and severity
【24h】

HLA-DRB1 alleles in Egyptian rheumatoid arthritis patients: Relations to anti-cyclic citrullinated peptide antibodies, disease activity and severity

机译:埃及类风湿关节炎患者的HLA-DRB1等位基因:与抗环瓜氨酸肽抗体,疾病活性和严重程度的关系

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Human leukocyte antigen HLA-DRB1 alleles encoding a common amino acid sequence called shared epitope in the third hypervariable region of DRB1 molecule have been identified as risk alleles for rheumatoid arthritis (RA). Aim of the work The aim was to study HLA-DRB1 01, 04 and 10 alleles in Egyptian RA patients and determine their relation with anticyclic citrullinated peptide (anti-CCP) antibody level, disease activity, clinical and radiological severity. Patients and methods The study involved 40 RA patients and 20 control. Simplified disease activity index (SDAI) was calculated, clinical severity was assessed using the mechanical joint score (MJS) and radiological severity evaluated using the simple erosion narrowing score (SENS). HLA-DRB1 genotyping and anti-CCP antibodies were detected. Results The mean patients’ age was 41.6 ± 12.7 years and disease duration 8.9 ± 7.7 years. The frequency of HLA DRB1 01, 04 and 10 in patients was 42.5%, 60% and 25% respectively. Of them 04 was significantly higher than in controls ( p = 0.013) and was associated with anti-CCP positive cases ( p = 0.0008) while the absence of HLA-DRB1 alleles was significantly associated with negative anti-CCP negative RA ( p = 0.0008). There were significant associations between HLA-DRB1 01 and 04 with SDAI ( p = 0.0002 and p = 0.005, respectively); between HLA-DRB1 04 and 10 with SENS ( p = 0.002 and p = 0.001 respectively) and between HLA-DRB1 01, 04 and 10 with MJS ( p = 0.02, p = 0.03 and p = 0.02, respectively). Conclusion HLA-DRB1 04 is associated with RA in Egyptian patients and is strongly associated in the production of elevated titers of anti-CCP antibodies which contribute to the development, severity and activity of the disease.
机译:背景技术已将人类白细胞抗原HLA-DRB1等位基因编码为类风湿关节炎(RA)的风险等位基因,该等位基因编码DRB1分子第三高变区中称为共享表位的共有氨基酸序列。工作目的目的是研究埃及RA患者的HLA-DRB1 01、04和10等位基因,并确定它们与抗环瓜氨酸肽(anti-CCP)抗体水平,疾病活性,临床和放射学严重程度的关系。患者和方法该研究涉及40位RA患者和20位对照。计算简化的疾病活动指数(SDAI),使用机械关节评分(MJS)评估临床严重性,并使用简单侵蚀缩小评分(SENS)评估放射线严重性。检测到HLA-DRB1基因分型和抗CCP抗体。结果患者平均年龄为41.6±12.7岁,病程为8.9±7.7岁。患者的HLA DRB1、01、04和10的发生率分别为42.5%,60%和25%。其中04显着高于对照组(p = 0.013),并且与抗CCP阳性病例相关(p = 0.0008),而HLA-DRB1等位基因的缺失与抗CCP阴性RA显着相关(p = 0.0008) )。 HLA-DRB1 01和04与SDAI之间存在显着关联(分别为p = 0.0002和p​​ = 0.005);使用SENS的HLA-DRB1 04和10之间(分别为p = 0.002和p​​ = 0.001)和使用MJS的HLA-DRB1 01、04和10之间(分别为p = 0.02,p = 0.03和p = 0.02)。结论HLA-DRB1 04与埃及患者的RA相关,并且与抗CCP抗体滴度升高的产生密切相关,这有助于该疾病的发展,严重程度和活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号